Join Growin Stock Community!

Evogene ltd.EVGN.US Overview

US StockHealthcare
(No presentation for EVGN)
My Watchlist

Ticker

Value

empty

There is no following symbol in this watchlist.

EVGN AI Insights

EVGN Overall Performance

EVGN AI Analysis & Strategy

AI Strategy

Browsing restrictions can be lifted for a fee.

EVGN Recent Performance

-2.03%

Evogene ltd.

0.05%

Avg of Sector

-0.31%

S&P500

EVGN PowerScanner

Introduction >>

Power Squeeze

Surfing Trend

1 Day

1 Week

1 Month

EVGN Key Information

EVGN Financial Forecast

chart

Browsing restrictions can be lifted for a fee.

QuarterlyEPS ForecastQoQMaxMin
2026Q1
2026Q2
2026Q3
2026Q4
2027Q1

EVGN Profile

Evogene Ltd., together with its subsidiaries, operates as a computational biology company. It focuses on product discovery and development in multiple life-science based industries, including human health and agriculture, through the use of its Computational Predictive Biology (CPB) platform. The CPB platform, incorporating a deep understanding of biology leveraged through big data and artificial intelligence, designed to computationally discover and uniquely guide the development of life-science products based on microbes, small molecules, and genetic elements. The company operates through three segments: Agriculture, Human Health, and Industrial Applications. The Agriculture segment develops seed traits, ag-chemical products, and ag-biological products to enhance plant performance. Its products focus on various crops, such as corn, soybean, wheat, rice, and cotton. The Industrial Applications segment develops enhanced castor bean seeds to serve as a feedstock source for other industrial uses. The Human Health segment discovers and develops human microbiome-based therapeutics for the treatment of immuno-oncology, GI related disorders, and antimicrobial resistance organisms. The company also provides medical cannabis products. It operates in the United States, Israel, Brazil, and internationally. The company has strategic collaborations and licensing agreements with agricultural companies, such as BASF SE, Corteva, and Bayer; and through its subsidiary, Canonic Ltd., has a collaboration agreement with Cannbit Ltd. for the development of novel medical cannabis products. Evogene Ltd. was founded in 1999 and is headquartered in Rehovot, Israel.

Price of EVGN

EVGN FAQ

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

EVGN Earnings Table

Unit : USD

QTRNon-GAAP EPSEPS YoYEPS Surprise %SalesSales YoYSales Surprise %NPM
Current
2025Q4
2025Q3
2025Q2
2025Q1
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-0.32
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
1.01
PB Ratio
6.39
Price-to-FCF
-
METRIC
VALUE
vs. INDUSTRY
Gross Margin
50.19%
Net Margin
-53.38%
Revenue Growth (YoY)
-31.13%
Profit Growth (YoY)
-49.83%
3-Year Revenue Growth
-12.52%
3-Year Profit Growth
-23.48%
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-0.32
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
1.01
PB Ratio
6.39
Price-to-FCF
-
Gross Margin
50.19%
Net Margin
-53.38%
Revenue Growth (YoY)
-31.13%
Profit Growth (YoY)
-49.83%
3-Year Revenue Growth
-12.52%
3-Year Profit Growth
-23.48%

  • When is EVGN's latest earnings report released?

    The most recent financial report for Evogene ltd. (EVGN) covers the period of 2025Q3 and was published on 2025/09/30. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating EVGN's short-term business performance and financial health. For the latest updates on EVGN's earnings releases, visit this page regularly.

  • What is the operating profit of EVGN?

    According to the latest financial report, Evogene ltd. (EVGN) reported an Operating Profit of -2.72M with an Operating Margin of -873.08% this period, representing a growth of 63.46% compared to the same period last year. Operating Profit reflects the company's core business efficiency and cost control, making it a key indicator for evaluating operational strength and profitability.

  • How is EVGN's revenue growth?

    In the latest financial report, Evogene ltd. (EVGN) announced revenue of 312K, with a Year-Over-Year growth rate of -82.63%. Revenue growth can be driven by product mix changes, market share expansion, price adjustments, or international market penetration. Investors should also monitor gross margin and regional revenue distribution for a comprehensive view of growth quality and sustainability.

  • How much debt does EVGN have?

    As of the end of the reporting period, Evogene ltd. (EVGN) had total debt of 2.52M, with a debt ratio of 0.1. Long-term debt comprises a higher/lower proportion. The level of financial leverage directly impacts the company's capital structure and interest coverage. If debt is high, pay attention to interest expenses and refinancing risks. Conversely, a low-leverage structure indicates greater risk tolerance but potentially less growth flexibility.

  • How much cash does EVGN have?

    At the end of the period, Evogene ltd. (EVGN) held Total Cash and Cash Equivalents of 5.63M, accounting for 0.22 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.

  • Does EVGN go with three margins increasing?

    In the latest report, Evogene ltd. (EVGN) did not achieve the “three margins increasing” benchmark, with a gross margin of 49.7%%, operating margin of -873.08%%, and net margin of 1,241.7%%. This demonstrates limited improvement in profitability, which is a key signal for fundamental analysis. Investors should consider margin trends alongside other financial indicators to assess EVGN's profit trajectory and future growth potential.

  • Is EVGN's EPS continuing to grow?

    According to the past four quarterly reports, Evogene ltd. (EVGN)'s earnings per share (EPS) shows a steady growth trend, with the latest EPS at 0.44. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.

  • What is the FCF of EVGN?

    Evogene ltd. (EVGN)'s Free Cash Flow (FCF) for the period is -3.31M, calculated as Operating Cash Flow minus Capital Expenditures, representing a rise of 34% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.

  • What are the PEG ratio and PE ratio of EVGN?

    The latest valuation data shows Evogene ltd. (EVGN) has a Price-To-Earnings (PE) ratio of -3.42 and a Price/Earnings-To-Growth (PEG) ratio of -0. A PEG below 1 usually suggests the market is underestimating growth potential, while a PEG above 1 indicates high growth expectations are already priced in. Investors should conduct a comprehensive valuation by considering historical growth, market forecasts, and industry cycles.